Literature DB >> 27467947

Targeting STAT3 signaling reduces immunosuppressive myeloid cells in head and neck squamous cell carcinoma.

Lin-Lin Bu1, Guang-Tao Yu2, Wei-Wei Deng2, Liang Mao2, Jian-Feng Liu2, Si-Rui Ma2, Teng-Fei Fan2, Bradford Hall3, Ashok B Kulkarni3, Wen-Feng Zhang1, Zhi-Jun Sun4.   

Abstract

Cumulative evidence suggests that constitutively activated signal transducer and activator of transcription (STAT3) may contribute to sustaining immunosuppressive status, and that inhibiting STAT3 signaling represents a potential strategy to improve antitumor immunity. In the present study, we observed that high levels phosphorylated of STAT3 are significantly associated with the markers for both myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) in human head and neck squamous cell carcinoma (HNSCC). Additionally, we showed that targeting STAT3 signaling with a tolerable selective inhibitor S3I-201 significantly decreased immature myeloid cells such as MDSCs, TAMs and iDCs in genetically defined mice HNSCC model. These findings highlight that targeting STAT3 signaling may be effective to enhance antitumor immunity via myeloid suppressor cells in HNSCC.

Entities:  

Keywords:  Head and neck squamous cell carcinoma; STAT3; myeloid-derived suppressor cells; tumor-associated macrophages

Year:  2016        PMID: 27467947      PMCID: PMC4910719          DOI: 10.1080/2162402X.2015.1130206

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  43 in total

Review 1.  Global epidemiology of oral and oropharyngeal cancer.

Authors:  Saman Warnakulasuriya
Journal:  Oral Oncol       Date:  2008-09-18       Impact factor: 5.337

2.  Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells.

Authors:  Masahisa Jinushi; Shigeki Chiba; Hironori Yoshiyama; Kenkichi Masutomi; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Hideo Yagita; Akinori Takaoka; Hideaki Tahara
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-11       Impact factor: 11.205

3.  Targeting tumor-associated myeloid cells for cancer immunotherapy.

Authors:  Hong Qin; Guowei Wei; Dongho Gwak; Zhenyuan Dong; Ailian Xiong; Larry W Kwak
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

4.  Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-alpha: down-regulation of IL-12 responsiveness and inhibition of dendritic cell activation.

Authors:  S Latour; H Tanaka; C Demeure; V Mateo; M Rubio; E J Brown; C Maliszewski; F P Lindberg; A Oldenborg; A Ullrich; G Delespesse; M Sarfati
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

Review 5.  STAT3: a target to enhance antitumor immune response.

Authors:  Heehyoung Lee; Sumanta Kumar Pal; Karen Reckamp; Robert A Figlin; Hua Yu
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

6.  Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway.

Authors:  Yulia Nefedova; Srinivas Nagaraj; Amsler Rosenbauer; Carlos Muro-Cacho; Said M Sebti; Dmitry I Gabrilovich
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

Review 7.  Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway.

Authors:  Takashi Matozaki; Yoji Murata; Hideki Okazawa; Hiroshi Ohnishi
Journal:  Trends Cell Biol       Date:  2009-01-12       Impact factor: 20.808

8.  STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity.

Authors:  Thomas Welte; Samuel S M Zhang; Tian Wang; Zhiyuan Zhang; David G T Hesslein; Zhinan Yin; Arihiro Kano; Yoshiki Iwamoto; En Li; Joseph E Craft; Alfred L M Bothwell; Erol Fikrig; Pandelakis A Koni; Richard A Flavell; Xin-Yuan Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-05       Impact factor: 11.205

9.  Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants.

Authors:  Kipp Weiskopf; Aaron M Ring; Peter J Schnorr; Jens-Peter Volkmer; Anne Kathrin Volkmer; Irving L Weissman; K Christopher Garcia
Journal:  Oncoimmunology       Date:  2013-07-29       Impact factor: 8.110

10.  Adaptive immune resistance in HPV-associated head and neck squamous cell carcinoma.

Authors:  Sara I Pai
Journal:  Oncoimmunology       Date:  2013-05-01       Impact factor: 8.110

View more
  11 in total

1.  STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC.

Authors:  L L Bu; G T Yu; L Wu; L Mao; W W Deng; J F Liu; A B Kulkarni; W F Zhang; L Zhang; Z J Sun
Journal:  J Dent Res       Date:  2017-06-12       Impact factor: 6.116

Review 2.  Therapeutic Targeting of Tumor Cells and Tumor Immune Microenvironment Vulnerabilities.

Authors:  Balaraman Kalyanaraman; Gang Cheng; Micael Hardy
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

3.  MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment.

Authors:  Yu-Ting Su; Madison Butler; Meili Zhang; Wei Zhang; Hua Song; Lee Hwang; Andy D Tran; Ryan E Bash; Allison N Schorzman; Ying Pang; Guangyang Yu; William C Zamboni; Xiaodong Wang; Stephen V Frye; Christopher Ryan Miller; Dragan Maric; Masaki Terabe; Mark R Gilbert; Henry Shelton Earp Iii; Jing Wu
Journal:  Neurooncol Adv       Date:  2020-06-03

Review 4.  Exploiting the tumor immune microenvironment and immunometabolism using mitochondria-targeted drugs: Challenges and opportunities in racial disparity and cancer outcome research.

Authors:  Balaraman Kalyanaraman
Journal:  FASEB J       Date:  2022-04       Impact factor: 5.834

5.  Selective blockade of B7-H3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma.

Authors:  Liang Mao; Teng-Fei Fan; Lei Wu; Guang-Tao Yu; Wei-Wei Deng; Lei Chen; Lin-Lin Bu; Si-Rui Ma; Bing Liu; Yansong Bian; Ashok B Kulkarni; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  J Cell Mol Med       Date:  2017-04-11       Impact factor: 5.310

6.  Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma.

Authors:  Si-Rui Ma; Wei-Wei Deng; Jian-Feng Liu; Liang Mao; Guang-Tao Yu; Lin-Lin Bu; Ashok B Kulkarni; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  Mol Cancer       Date:  2017-06-07       Impact factor: 27.401

Review 7.  Modulation of Immunosuppression by Oligonucleotide-Based Molecules and Small Molecules Targeting Myeloid-Derived Suppressor Cells.

Authors:  Jihyun Lim; Aram Lee; Hee Gu Lee; Jong-Seok Lim
Journal:  Biomol Ther (Seoul)       Date:  2020-01-01       Impact factor: 4.634

Review 8.  STAT3 pathway in cancers: Past, present, and future.

Authors:  Han-Qi Wang; Qi-Wen Man; Fang-Yi Huo; Xin Gao; Hao Lin; Su-Ran Li; Jing Wang; Fu-Chuan Su; Lulu Cai; Yi Shi; Bing Liu; Lin-Lin Bu
Journal:  MedComm (2020)       Date:  2022-03-23

9.  Factors Influencing the Differentiation of Human Monocytic Myeloid-Derived Suppressor Cells Into Inflammatory Macrophages.

Authors:  Defne Bayik; Debra Tross; Dennis M Klinman
Journal:  Front Immunol       Date:  2018-03-26       Impact factor: 7.561

Review 10.  Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma.

Authors:  Florencia Veigas; Yamil D Mahmoud; Joaquin Merlo; Adriana Rinflerch; Gabriel Adrian Rabinovich; María Romina Girotti
Journal:  Cancers (Basel)       Date:  2021-03-01       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.